ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Revenue: ZYNLONTA net product revenue was $15.8 million in Q3 2025, in line with the recent quarterly run rate, but down from $18 million last year.
Expenses & Loss: Operating expenses dropped 12.1% year-on-year, and net loss narrowed to $41 million from $44 million in Q3 2024.
Cash Runway: Completed a $60 million private placement after quarter-end, extending cash runway to at least 2028 with pro forma cash of $292.3 million.
Clinical Progress: Encouraging data from key ZYNLONTA trials in DLBCL and follicular lymphoma; LOTIS-5 Phase III and LOTIS-7 Phase Ib progressing with key data updates expected in late 2025 and first half of 2026.
Future Growth: Management sees potential to double the addressable patient base and ramp up revenues to $200–300 million in second-line DLBCL and up to $600 million to $1 billion across broader indications, pending trial outcomes and regulatory approvals.
Guidance: Revenue expected to ramp in the two years following potential approvals and compendia inclusion around first half of 2027.
